These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 10606257)

  • 1. Oral fluoropoyrimidines.
    Hoff PM; Royce M; Medgyesy D; Brito R; Pazdur R
    Semin Oncol; 1999 Dec; 26(6):640-6. PubMed ID: 10606257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New drugs in therapy of colorectal cancer: preclinical studies.
    Rustum YM; Cao S
    Semin Oncol; 1999 Dec; 26(6):612-20. PubMed ID: 10606254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin (ORZEL) and S-1: a review of their clinical development and therapeutic potential.
    Hoff PM
    Invest New Drugs; 2000 Nov; 18(4):331-42. PubMed ID: 11081569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines: a novel class of oral antineoplastic agents.
    Hoff PM; Pazdur R
    Semin Oncol; 1999 Dec; 26(6 Suppl 18):52-6. PubMed ID: 10892578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [5-fluorouracil and dihydropyrimidine dehydrogenase].
    Kubota T
    Gan To Kagaku Ryoho; 2001 Apr; 28(4):433-9. PubMed ID: 11329775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral DPD-inhibitory fluoropyrimidine drugs.
    Diasio RB
    Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):19-23. PubMed ID: 11098485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Fluorinated pyrimidines in oral treatment of advanced colorectal cancer].
    Todnem K; Harboe K; Zotova L; Lind A; Ogreid D
    Tidsskr Nor Laegeforen; 2000 Sep; 120(23):2781-5. PubMed ID: 11107924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluoropyrimidines: a critical evaluation.
    Brito RA; Medgyesy D; Zukowski TH; Royce ME; Ravandi-Kashani F; Hoff PM; Pazdur R
    Oncology; 1999 Jul; 57 Suppl 1():2-8. PubMed ID: 10436410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral fluoropyrimidines in colorectal cancer.
    Van Cutsem E; Peeters M
    Semin Oncol; 2000 Oct; 27(5 Suppl 10):91-5. PubMed ID: 11049039
    [No Abstract]   [Full Text] [Related]  

  • 10. Mechanism of action of fluoropyrimidines: relevance to the new developments in colorectal cancer chemotherapy.
    Sobrero A; Guglielmi A; Grossi F; Puglisi F; Aschele C
    Semin Oncol; 2000 Oct; 27(5 Suppl 10):72-7. PubMed ID: 11049035
    [No Abstract]   [Full Text] [Related]  

  • 11. Practical considerations in the use of oral fluoropyrimidines.
    Hoff PM
    Semin Oncol; 2003 Jun; 30(3 Suppl 6):88-92. PubMed ID: 12802799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical implications of dihydropyrimidine dehydrogenase inhibition.
    Diasio RB
    Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):17-21. PubMed ID: 10442353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral therapy for colorectal cancer: how to choose.
    Damjanov N; Meropol NJ
    Oncology (Williston Park); 2000 Jun; 14(6):799-807; discussion 807-8, 813-4,. PubMed ID: 10887632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dihydropyrimidine dehydrogenase (DPD) activity in gastric cancer tissue and effect of DPD inhibitory fluoropyrimidines.
    Usuki H; Ishimura K; Yachida S; Hagiike M; Okano K; Izuishi K; Karasawa Y; Goda F; Maeta H
    Gastric Cancer; 2003; 6 Suppl 1():66-70. PubMed ID: 12775023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving 5-FU with a novel dihydropyrimidine dehydrogenase inactivator.
    Diasio RB
    Oncology (Williston Park); 1998 Mar; 12(3 Suppl 4):51-6. PubMed ID: 9556784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor 5-FU-related mRNA Expression and Efficacy of Oral Fluoropyrimidines in Adjuvant Chemotherapy of Colorectal Cancer.
    Koda K; Miyauchi H; Kosugi C; Kaiho T; Takiguchi N; Kobayashi S; Maruyama T; Matsubara H;
    Anticancer Res; 2016 Oct; 36(10):5325-5331. PubMed ID: 27798895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines.
    Omura K
    Int J Clin Oncol; 2003 Jun; 8(3):132-8. PubMed ID: 12851836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase.
    Schilsky RL; Kindler HL
    Expert Opin Investig Drugs; 2000 Jul; 9(7):1635-49. PubMed ID: 11060767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral fluoropyrimidine treatment of colorectal cancer.
    Eng C; Kindler HL; Schilsky RL
    Clin Colorectal Cancer; 2001 Aug; 1(2):95-103. PubMed ID: 12445367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule.
    Guo XD; Harold N; Saif MW; Schuler B; Szabo E; Hamilton JM; Monahan BP; Quinn MG; Cliatt J; Nguyen D; Grollman F; Thomas RR; McQuigan EA; Wilson R; Takimoto CH; Grem JL
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):79-85. PubMed ID: 12707718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.